← SUPERNUS PHARMACEUTICALS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $91.2m $57.3m $111.0m $113.1m $127.0m $53.4m $60.7m $1.3m $73.9m ($38.5m)
Net Income (Loss) Available to Common Stockholders, Basic $91.2m $57.3m $111.0m $113.1m $127.0m $53.4m $64.3m $1.3m $73.9m ($38.5m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — $57.3m — — — — — — — —
Depreciation, Depletion and Amortization $2.4m $8.1m $7.1m $6.7m $18.1m $32.6m $85.5m $84.9m $80.4m $91.6m
Amortization of Debt Issuance Costs and Discounts $520k $50k $11.8m $15.7m $16.6m $17.5m $2.1m $532k $0 $0
Amortization of Intangible Assets $1.3m $6.9m $5.2m $5.2m $15.7m $30.0m $82.6m $82.4m $78.0m $89.5m
Deferred Income Tax Expense (Benefit) ($41.8m) $21.2m ($4.2m) ($5.8m) $568k ($5.0m) ($26.3m) ($25.7m) ($20.1m) $5.2m
Share-based Payment Arrangement, Noncash Expense $5.9m $8.4m $11.3m $14.8m $16.6m $17.9m $17.6m $26.8m $27.8m $33.1m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — $2.0m $2.7m $4.2m
Share-based Payment Arrangement, Expense $5.9m $8.4m $11.3m $14.8m $16.6m $17.9m $17.6m $26.8m $27.8m $56.0m
Goodwill, Impairment Loss — — — — — — — $0 $0 $0
Impairment of Intangible Assets (Excluding Goodwill) — — — — — — — $20.2m $0 $0
Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss — — ($8k) — — — — $0 ($9k) $439k
Equity Method Investment, Realized Gain (Loss) on Disposal — — — — — — $12.9m $0 $0 —
Gain (Loss) on Extinguishment of Debt ($671k) ($295k) — $0 — — — — — —
Income Tax Expense (Benefit) ($40.9m) $43.3m $29.2m $34.4m $41.7m $19.8m $32k $1.5m $24.0m ($10.5m)
Interest Expense Nonoperating — — — — — — — $2.4m $0 $0
Other Nonoperating Income (Expense) ($15k) — — ($1.1m) ($5.0m) ($12.9m) $14.6m $10.5m $16.2m $13.3m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $15.6m $24.1m $35.9m ($15.8m) $34.6m ($3.9m) $16.4m ($18.8m) ($2.1m) $22.3m
Increase (Decrease) in Inventories $4.2m ($497k) $9.4m $969k $10.1m $14.6m $17.9m ($6.1m) ($15.8m) $7.5m
Increase (Decrease) in Accounts Payable $3.5m ($620k) ($3.6m) $7.0m — — — — — —
Proceeds from Stock Options Exercised — — — — — — — $4.3m $6.8m $34.9m
Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded — — — — $0 — — — — —
Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Not Previously Recorded — — — — — — — $0 $0 $0
Debt Securities, Available-for-sale, Realized Gain (Loss) — — — — — — — $0 ($9k) ($439k)
Goodwill — — — — $77.9m $117.5m $117.0m $117.0m $117.0m $124.9m
Inventory Write-down — — — — — — — $8.0m $8.9m $1.9m
Investment Income, Interest $1.5m $2.9m $13.8m — — — — — — —
Nonoperating Income (Expense) ($3.8m) $1.1m ($4.3m) — — — — $8.0m $16.2m $13.3m
Unrealized Gain (Loss) on Derivatives $448k $76k — $0 ($1.9m) $6.5m — — — —
Derivative, Gain (Loss) on Derivative, Net — — — $0 — — — — — —
Gain (Loss) on Derivative Instruments, Net, Pretax $448k $76k — — — — — — — —
Net Cash Provided by (Used in) Operating Activities $66.8m $114.6m $129.0m $143.1m $138.4m $127.1m $116.8m $111.1m $172.0m $47.3m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $1.6m $2.0m $844k $2.7m $3.4m $25k $412k $551k $725k $1.3m
Payments to Acquire Businesses, Net of Cash Acquired — — — — $298.5m $950k $0 — — $293.1m
Net Cash Provided by (Used in) Investing Activities ($36.0m) ($86.4m) ($413.5m) ($157.9m) ($34.7m) ($81.9m) ($216.7m) $268.7m ($189.9m) $4.1m
Cash flows from financing activities:
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale — — — — — — — $370.9m $498.9m $774.5m
Proceeds from Issuance of Common Stock $2.1m $5.7m $11.6m $3.9m $4.4m $7.1m $12.4m $6.6m $14.9m $37.6m
Net Cash Provided by (Used in) Financing Activities $2.1m $5.7m $376.4m $3.9m $3.6m ($130.4m) ($10.5m) ($397.9m) $12.2m $9.1m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — $33.9m $91.9m ($10.9m) $107.3m ($85.2m) ($110.3m) ($18.1m) ($5.7m) $60.6m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $33.9m $192.2m $181.4m $288.6m $203.4m $93.1m $75.1m $69.3m $129.9m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $493k $134k $1.3m $2.5m $2.5m $2.5m $2.5m $1.9m $0 $0
Income Taxes Paid, Net — $1.6m $34.8m $51.5m $45.4m $25.2m $16.2m $36.6m $53.3m $16.1m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.